An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This study will assess the prophylactic effect of pegfilgrastim (Neulastim) on febrile and/or
Grade IV neutropenia in participants receiving chemotherapy (CT) or immunochemotherapy (ICT)
as first or second line treatment for NHL. Pegfilgrastim will be administered at a fixed dose
of 6 milligrams (mg) subcutaneously 24 hours after the last dose of CT or ICT in each
treatment cycle.